North Star Asset Management Inc. Has $28.53 Million Holdings in AbbVie Inc. (NYSE:ABBV)

North Star Asset Management Inc. raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 1.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,564 shares of the company's stock after buying an additional 3,004 shares during the quarter. AbbVie makes up approximately 1.3% of North Star Asset Management Inc.'s holdings, making the stock its 21st largest holding. North Star Asset Management Inc.'s holdings in AbbVie were worth $28,532,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Crestline Management LP grew its holdings in shares of AbbVie by 438.4% during the 4th quarter. Crestline Management LP now owns 35,311 shares of the company's stock worth $6,275,000 after purchasing an additional 28,753 shares during the period. Dimensional Fund Advisors LP lifted its holdings in AbbVie by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 9,367,162 shares of the company's stock worth $1,664,489,000 after acquiring an additional 108,993 shares during the last quarter. Quantbot Technologies LP lifted its holdings in shares of AbbVie by 35.8% in the 4th quarter. Quantbot Technologies LP now owns 1,047 shares of the company's stock worth $186,000 after purchasing an additional 276 shares during the last quarter. AXA S.A. lifted its stake in AbbVie by 14.8% in the fourth quarter. AXA S.A. now owns 971,893 shares of the company's stock valued at $172,705,000 after buying an additional 125,568 shares during the last quarter. Finally, Keystone Financial Group raised its stake in AbbVie by 0.9% during the 4th quarter. Keystone Financial Group now owns 17,952 shares of the company's stock valued at $3,190,000 after acquiring an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on ABBV. Citigroup reissued a "neutral" rating and set a $205.00 target price (down previously from $210.00) on shares of AbbVie in a report on Wednesday, May 14th. Guggenheim boosted their target price on shares of AbbVie from $214.00 to $216.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. BNP Paribas upgraded AbbVie to a "hold" rating in a report on Thursday, May 8th. Morgan Stanley upped their target price on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday, April 28th. Finally, BMO Capital Markets increased their price target on shares of AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a research note on Monday, February 3rd. Eight research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $210.95.

AbbVie Stock Performance

ABBV traded up $2.11 during trading on Thursday, reaching $185.20. 2,036,349 shares of the company's stock were exchanged, compared to its average volume of 6,232,934. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The business has a 50 day moving average price of $186.76 and a 200 day moving average price of $186.09. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $218.66. The company has a market capitalization of $327.14 billion, a P/E ratio of 77.24, a PEG ratio of 1.62 and a beta of 0.56.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The company had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same period in the previous year, the business earned $2.31 earnings per share. The company's quarterly revenue was up 8.4% on a year-over-year basis. As a group, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Insider Buying and Selling at AbbVie

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the transaction, the executive vice president now owns 53,234 shares of the company's stock, valued at $11,183,398.72. This represents a 52.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.08% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.